REFERENCES

 Bifidobacterium lactis BL-34

1. Mitsuoka, T. (1996). Intestinal flora and human health. Asia Pacific J. Clin. Nutr. 5:2-9.

2. Meile, L., Ludwig, W., Rueger, U., Gut, C., Kaufmann, P., Dasen, G., Wenger, S. & Teuber, M. (1997). Bifidobacterium lactis sp. nov., a moderately oxygen tolerant species isolated from fermented milk. Syst. Appl. Microbiol. 20:57-64.

3. Masco, L., Ventura, M., Zink, R., Huys, G. & Swings, J. (2004). Polyphasic taxonomic analysis of Bifidobacterium animalis and Bifidobacterium lactis reveals relatedness at the subspecies level: reclassification of Bifidobacterium animalis subsp. Animalis subsp. nov. and Bifidobacterium lactis as Bifidobacterium animalis subsp. lactis subsp. nov. Int. J. System. Evol. Microbiol. 54:1137-1143.

4. Ventura, V. & Zink, R. (2002). Rapid identification, differentiation, and proposed new taxonomic classification of Bifidobacterium lactis. Appl. Environ. Microbiol. 68(12):6429-6434.

5. Aguirre, M. & Collins, M.D. (1993). Lactic acid bacteria and human clinical infections.

J. Appl. Bact. 75:95-107.

6. Gasser, F. (1994). Safety of lactic acid bacteria and their occurrence in human clinical infections. Bull Inst Pasteur 92: 45-67.

7. Salminen, S., von Wright, A., Morelli, L., Marteau, P., Brassart, D., de Vos, W.M.,

Fonden, R., Saxelin, M., Collins, K., Mogensen, G., Birkeland, S.-E. & Mattila-

Sandholm, T. (1998). Demonstration of safety of probiotics-a review.

Int. J. Food Prot. 44:93-106.

8. Boyle, R.J., Robins-Browne, R.M. & Tang, M.L. (2006). Probiotic use in clinical practice: what are the risks? Am J. Clin Nutr. 83(6):1256-64.

9. Borriello, S.P., Hammes, W.P., Holzapfel, W., Marteau, P., Schrezenmeir, J., Vaara, M. & Valtonen, V. (2003). Safety of probiotics that contain lactobacilli or bifidobacteria.

Clin. Infect Dis. 36:775-780.

10. Mogensen, G., Salminen, S., O’Brien, J., Ouwehand, A.C., Holzapfel, W., Shortt, C., Fonden, R., Miller, G.D., Donohue, D., Playne, M., Crittenden, R., Salvadori, B. & Zink, R. (2002). Inventory of microorganisms with a documented history of safe use in food. Bulletin of the International Dairy Federation. 377:10-19.

11. Engelbrektson, A.L., Korzenik, J.R., Pittler, A., Sanders, M.E., Klaenhammer, T.R. & Kitts, C.L. (2007). A randomized, double blind, controlled trial of probiotics to minimize the disruption of fecal microbiota in healthy subjects undergoing antibiotic therapy. Manuscript submitted.

12. Bartosch, S., Woodmansey, E.J., Paterson, J.C.M., McMurdo, M.E.T. & Macfarlane, G.T. (2005). Microbiological effects of consuming a symbiotic containing Bifidobacterium bifidum, bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerise chain reaction and counting of viable bacteria. Clinical Infectious Diseases. 40:28-37.

13. Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A., & Pot, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology.

13(2):236-243.

14. Lammers, K.M., Brigidi, P., Vitali, B., Gionchetti, P., Rizello, F., Caramelli, E., Matteuzzi, D. & Campieri, M. (2003). Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunology and Medical

Microbiology. 38:165-172.

15.  Delcour, J., Ferain, T., Deghorain, M., Palumbo, E. & Hols, P. (1999). The biosynthesis and functionality of the cellwall of lactic acid bacteria. Antonie Van Leeuwenhoek. 76(1-4):159-84.